0001193125-26-083096
SEC filingCryo-Cell International, Inc. reported revenue of $31.6 million for fiscal year 2025, ending November 30, 2025. The company generated operating income of $482,000, but recorded a net loss of $2.4 million, primarily due to significant impairment charges totaling $17.5 million ($4.4 million for public inventory and $13.1 million for Duke assets) and interest expense of $2.1 million. The balance sheet shows total assets of $61.7 million, with substantial deferred tax assets of $23.6 million, but also reveals a stockholders' deficit of $18.6 million. Cash flow from operations was positive at $5.5 million, though the company paid $3.2 million in dividends and had a net decrease in cash of $242,000. The company maintains significant deferred revenue liabilities totaling $60.7 million ($9.7 million current, $51.0 million long-term).
Cryo-Cell International reported fiscal year 2025 results with revenue of $31.6 million. The company achieved operating income of $482,000 but recorded a net loss of $2.4 million. This loss was driven by substantial impairment charges totaling $17.5 million ($4.4 million for public inventory and $13.1 million for Duke assets) and interest expense of $2.1 million. The company's weighted average common shares outstanding were 8.1 million, with net loss per share reported as -$0. The balance sheet shows total assets of $61.7 million, but stockholders' deficit of $18.6 million, primarily due to accumulated deficit of $38.4 million and treasury stock of $25.0 million.
Revenue of $31.6 million was generated from the company's operations. The document does not provide segment breakdown, geographic mix, or specific growth drivers beyond the aggregate revenue figure. No comparative prior period revenue figure is provided in the XBRL data or document text, preventing year-over-year analysis. The revenue appears to be derived from the company's core business operations, but specific revenue drivers or segment performance details are not disclosed in the provided information.
Gross profit was $24.2 million (revenue of $31.6 million minus cost of sales of $7.4 million), resulting in a gross margin of 76.6%. Operating income of $482,000 represents an operating margin of 1.5%. The company incurred significant expenses including selling, general and administrative expenses of $18.2 million, research and development expenses of $376,000, and depreciation and amortization of $751,000. The substantial impairment charges of $17.5 million significantly impacted profitability, turning what would have been operating income into a pre-tax loss of $2.3 million before considering other expenses.
Cash flow from operations was positive at $5.5 million, driven by net loss of $2.4 million adjusted for non-cash items including depreciation and amortization of $985,000, impairment charges of $4.4 million, and changes in working capital. Free cash flow (operating cash flow of $5.5 million minus capital expenditures of $230,000) was $4.5 million. The balance sheet shows total assets of $61.7 million, including current assets of $11.8 million (with cash of $319,000) and property and equipment of $21.0 million. Total liabilities are $80.3 million, including current liabilities of $19.8 million and long-term deferred revenue of $51.0 million. The company has a line of credit of $2.3 million and notes payable totaling $8.4 million.
The document includes standard risk factor disclosures but does not provide specific management guidance, forward-looking financial projections, or strategic priorities for future periods. The risk factors section contains boilerplate language about forward-looking statements and cautions that actual results may differ materially from expectations. No quantitative guidance, revenue targets, or specific strategic initiatives are disclosed in the provided document content. The company qualifies all forward-looking statements with cautionary language about uncertainties and potential changes in views.